deltatrials
Completed PHASE4 NCT01199198

Tolvaptan in Hyponatremic Cancer Patients

Randomized Placebo-Controlled Trial of Tolvaptan in Hyponatremic Patients With Cancer

Sponsor: M.D. Anderson Cancer Center

Conditions Advanced Cancers
Interventions Placebo Tolvaptan
Updated 7 times since 2017 Last updated: Sep 2, 2020 Started: May 31, 2011 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

Listed as NCT01199198, this PHASE4 trial focuses on Advanced Cancers and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 7 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  4. Oct 2020 — Jan 2021 [monthly]

    Completed PHASE4

  5. Jun 2018 — Oct 2020 [monthly]

    Completed PHASE4

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE4

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • Otsuka Pharmaceutical Development & Commercialization, Inc.
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Houston, United States